Updated 14:02 GMT, 29 Oct 2026 SPX 7,717.63 -0.34% NDX 29,430.34 -1.28% VIX 16.92 +0.06% GOLD 4,037.70 -0.34% CL 100.06 -2.65% BTC 80,234.72 -1.27%
Titan Protect
Join the Desk
NAS100 29,430 −1.28% S&P 7,718 −0.34% GOLD $4,038 −0.34% BTC $80,235 −1.27% VIX 16.92 +0.06% latest tape · as of 14:02 UTC
The Screen · Healthcare · Healthcare Plans

Elevance Health logoElevance Health

ELV · a US exchange · USD · Market cap $92.9B · 96,129 employees

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States.

Not yet scored
439.95 USD

Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago

Screened 2026-10-23 · the tape above runs as of 14:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price439.95 USD at the 23 Oct 2026 close
  • Our ratingFair value, current read accumulation
  • Ethical screenNot yet scored
  • OptionsOpen interest leans to puts (put/call 1.31)
  • Last reviewed23 Oct 2026 (6 days ago)

A summary of the dated readings below, not a live quote and not advice.

PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
488.40492.00814.00

What this means: price 439.95 against the desk's fair-value range, base estimate 492.00, over the last year.

Current read
Accumulation ?
FAIR VALUE · screened 2026-10-23
  • Trend Accumulation
  • Insiders insiders sold, $4,658,357, latest filing 2026-10-22
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 1.31, read 2026-10-28
  • Ethical screen not yet scored
Price439.95 USD
Fair value492.00
Ethical score77.3/100
RatingFAIR VALUE
Our investment reviews on this name
2026-10-15Read Accumulation412.70+6.6% to today ✓Markdown gives way to Accumulation
2026-10-11Read Markdown396.09+11.1% to today Markup gives way to Markdown
2026-10-02Read Markup396.09+11.1% to today ✓Accumulation gives way to Markup first Markup read since July
2026-08-27Read Accumulation396.28+11.0% to today ✓Markup gives way to Accumulation first Accumulation read since July

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

Daily reads →Latest news →The method →Compare →
The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Elevance Health holds its Accumulation at $439.95. The statistical read favours the buyers, held for 51 days.

As held on the ledger · 2026-10-23
PhaseAccumulation
Quantitative stateThe statistical read favours the buyers, held for 51 days
Price at the screen$439.95
Valuation18.84 trailing · 14.47 forward price to earnings
Values screenNot scored · score 77.3
Beta0.71
The Workings

Five Screens, Shown in Full

This security has not been fully scored against the values screen yet.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 26.38% Below 33% Interest-bearing debt is just 26.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 22.84% Below 33% Cash held in interest-bearing accounts and securities is 22.8% of assets, under the one-third limit. Pass
Receivables 16.10% Below 49% Money owed to the company is 16.1% of assets, under the 49% limit. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

The Read, in Plain English

Elevance Health clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.

2026-10-25

Elevance Health clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

2026-09-24 Clears

Elevance Health clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and almost none of its income is interest, so it passes.

Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads FAIR VALUE: it trades at roughly a 12% discount to our $492.00 fair value, weak competitive moat, 1.40% revenue growth.

488.40Conservative492.00Base case814.00Growth case 439.95Price

Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 11.8% margin of safety to the base estimate.

The Street's Range
393.00Street low 463.00Street average 492.00Street high 439.95Price

Third-party analyst targets: 21 covering, consensus Buy. The average target sits +5% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections
$538$404$269TODAY5y agoPROJECTIONOur fair value$492.00 +22%Street high$492.00 +22%Conservative$488.40 +21%Street avg$463.00 +15%

Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Health plans priced below their steady cash flows

Every month, families and employers hand over premiums that flow through a handful of big US insurers. Elevance sits among them, trading at 12.6 times forward earnings with revenue barely growing and a 2 percent profit margin. Our work puts fair value 32 percent higher, yet the weak moat and low returns on equity keep the shares at fair value rather than a bargain.

The 1 percent revenue growth and 11 percent ROE tell the real story. Scale helps, ethics clear the screen, and analysts see modest upside to 457 dollars, but nothing here suggests the business can widen its edge or accelerate.

Regulatory shifts, medical cost inflation and thin margins remain the live risks. A cyclical value trap is unlikely, yet the narrow moat leaves little room for error if policy or competition changes. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E14.5xexpensive even after accounting for its growth
Trailing P/E18.8xreasonably valued
EPS, trailing22.74
EPS, forward29.60
Revenue growth+1.4%slow but positive growth
Profit margin2.5%barely profitable
Return on equity11.1%a modest return on shareholder capital
FCF yield4.63%
Dividend yield1.73%
Debt to equity0.69moderate, manageable leverage
Current ratio1.52healthy short-term liquidity
Beta0.71steadier than the market
Short interest, float0.03%
52-week range274.84 - 436.24
MoatWEAK
Market cap$92.9B
Employees96,129

The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ELV trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-10-28 Accumulation $428.43 +0.0% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (21 analysts) rates it buy, with a mean price target of $401.

2026-10-21 Accumulation $428.43 +0.0% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (21 analysts) rates it buy, with a mean price target of $401. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-20 Accumulation $428.43 +0.0% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (21 analysts) rates it buy, with a mean price target of $401. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-19 Accumulation $428.43 +0.0% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (21 analysts) rates it buy, with a mean price target of $401. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-18 Accumulation $428.43 +0.0% Entry 13

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (21 analysts) rates it buy, with a mean price target of $401. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-17 Accumulation $428.43 +0.0% Entry 12

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (21 analysts) rates it buy, with a mean price target of $401. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-16 Accumulation $428.43 +3.8% Entry 11

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (21 analysts) rates it buy, with a mean price target of $401. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-15 Accumulation · changed $412.70 +0.0% Entry 10

The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (21 analysts) rates it buy, with a mean price target of $401. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-14 Markdown $412.70 +4.2% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (21 analysts) rates it buy, with a mean price target of $401. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-11 Markdown · changed $396.09 +0.0% Entry 8

The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (21 analysts) rates it buy, with a mean price target of $401.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on ELV

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ELV's Space
CICigna CVSCVS Health HUMHumana CNCCentene Corporation UNHUnitedHealth Group MOHMolina Healthcare, Inc.

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · ELV
DateInsiderTitleTypeSharesValue
2026-10-22 Kaye Mark EVP, CFO S - Sale 10,584 $4,658,357
2026-05-19 PENCZEK RONALD W Officer 1,531 $450,579
2026-05-19 PENCZEK RONALD W Officer 1,531 $617,192
2026-05-13 HAY LEWIS III Director 563 ·
2026-05-13 PERU RAMIRO G Director 563 ·
2026-05-13 SCHNEIDER RYAN M. Director 563 ·
2026-05-13 COLLIS STEVEN H Director 563 ·
2026-05-13 STRABLE-SOETHOUT DEANNA D Director 563 ·
2026-05-13 DEVORE SUSAN D Director 563 ·
2026-05-13 NERI ANTONIO F Director 563 ·

Public filings, recorded as found. The full tape lives at Insider Intelligence.

The Political Ledger · Congressional Disclosures
Disclosures naming ELV
DatePoliticianPartyTypeAmount
2026-07-20 Ro Khanna Democrat sell 1K–15K
2026-07-20 Ro Khanna Democrat sell 1K–15K
2026-05-15 Ro Khanna Democrat buy 1K–15K
2026-04-13 Ro Khanna Democrat Purchase 1K–15K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $381.75 +5.6% · $1,056 +5.6%
2 months $311.53 +29.4% · $1,294 +29.4%
3 months $287.89 +40.0% · $1,400 +40.0%
6 months $358.01 +12.6% $1.72 $1,131 +13.1%
1 year $377.55 +6.7% $6.85 $1,086 +8.6%
2 years $519.16 -22.4% $13.45 $802 -19.8%
3 years $449.46 -10.3% $18.04 $937 -6.3%
5 years $358.72 +12.3% $28.38 $1,203 +20.3%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ELV does next, these words stay.

Elevance Health · ELV · Accumulation · $439.95
Recorded 2026-10-23 · before the outcome · scored mechanically

All of today's entries → See the running score →
Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.